Halozyme Therapeutics (HALO) Stock Price, Quote, News & History | Benzinga

Halozyme Therapeutics Inc (HALO) Stock Price, Quote, News & History

HALONASDAQ

Trade with Public

Trade with Public

$105.35

-1.57-1.47%

At close: Aug 28, 5:00 PM EST

$105.35

N/A

After Hours: Aug 28, 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$106.45

Close

$105.35

Volume / Avg.

1.68M / 2.00M

Day Range

$104.70 - $106.81

52 Wk Range

61.23 - 109.66

Market Cap

$11.96B

P/E Ratio

31.35

Dividend Yield

-

Exchange

NASDAQ

RSI

67

Short Interest

16.9%

Days to Cover

5.01

Recent Halozyme Therapeutics, Inc. News

Top 3 Health Care Stocks That May Implode In August

3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.

Avi Kapoor

Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO, BTG, and ROAD.

Avi Kapoor

S&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today

U.S. payrolls fell 23,000 in July, gutting September Fed hike odds. The S&P 500 hit a record, while gold jumped to a seven-week high.

Piero Cingari

Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes including upgrades & downgrades on Benzinga analyst ratings page.

Avi Kapoor

Tech Stocks Rebound, Crude Rallies Above $64 On Iran Tensions: What's Moving Markets Wednesday?

Tech stocks recovered on Wednesday, led by a rally in battered software names, as the Nasdaq 100 jumped 1.4% past 25,000, outpacing the S&P 500's 1% gain and the Dow's 0.7% advance.

Piero Cingari

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

818.60M

Investing Cash Flow (TTM)

-605.72M

Financing Cash Flow (TTM)

-110.75M

Free Cash Flow (TTM)

518.45M

Capital Expenditure (TTM)

-300.14M

Net Change in Cash (TTM)

102.13M

Analyst Trends and Forecast

1

Apr

1

May

1

Jul

3

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$13.87B

PE Ratio (TTM)

31.35

PE Ratio (FWD)

14.51

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.85

PB Ratio (TTM)

84.52

Earnings Yield % (TTM)

3.19%

Earnings Yield % (FWD)

6.89%

EV / EBITDA (TTM)

19.55

Price / EBITDA (TTM)

18.19

Price / Free Cash Flow (TTM)

25.20

Book Value / Share

$1.26

Company Debt

Total Debt

$2.15B

LT Debt

$1.94B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$163.14M

Debt to Equity

14.95

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$106.45

Close

$105.35

Volume / Avg.

1.68M / 2.00M

Day Range

$104.70 - $106.81

52 Wk Range

61.23 - 109.66

Market Cap

$11.96B

P/E Ratio

31.35

Dividend Yield

-

Exchange

NASDAQ

RSI

67

Short Interest

16.9%

Days to Cover

5.01

About

Sector

Health Care

Industry

Biotechnology

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Halozyme Therapeutics (HALO) stock?

A

You can purchase shares of Halozyme Therapeutics (NASDAQ:HALO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Halozyme Therapeutics (HALO) competitors?

A

Other companies in Halozyme Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Halozyme Therapeutics (HALO) stock?

A

Halozyme Therapeutics has a consensus price target of $82.50.

Q

What is the current price for Halozyme Therapeutics (HALO)?

A

The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $105.35 last updated August 28, 2026 at 4:00 PM EDT.

Q

Does Halozyme Therapeutics (HALO) pay a dividend?

A

There are no upcoming dividends for Halozyme Therapeutics.

Q

When is Halozyme Therapeutics (NASDAQ:HALO) reporting earnings?

A

Halozyme Therapeutics does not have any upcoming earnings scheduled.

Q

Is Halozyme Therapeutics (HALO) going to split?

A

There is no upcoming split for Halozyme Therapeutics.

Q

What sector and industry does Halozyme Therapeutics (HALO) operate in?

A

Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.